Investigating a new skin therapy for a rare genetic skin disorder.
Study of the Safety, Tolerability, and Efficacy of an iPS Cell-based Therapy for Recessive Dystrophic Epidermolysis Bullosa Delivered with a Spray on Skin Device
This study is testing a new treatment for people with recessive dystrophic epidermolysis bullosa (RDEB) that uses special skin cells to help heal their fragile skin and reduce wounds, delivered through a handy spray directly to the problem areas.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-10721324 on NIH RePORTER |
What this research studies
This research focuses on recessive dystrophic epidermolysis bullosa (RDEB), a genetic condition that causes severe skin fragility and chronic wounds. The study aims to evaluate a novel therapy using induced pluripotent stem (iPS) cells to replace the missing collagen VII in the skin, which is crucial for skin integrity. Patients will receive this treatment through a specialized spray device that delivers the therapy directly to the affected areas. The goal is to assess both the safety and effectiveness of this innovative approach in promoting healing and reducing complications associated with RDEB.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with recessive dystrophic epidermolysis bullosa who experience chronic wounds and skin fragility.
Not a fit: Patients with other forms of epidermolysis bullosa or those who do not have the specific genetic mutations associated with RDEB may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a transformative treatment that significantly improves the quality of life for patients with RDEB by promoting skin healing and reducing the risk of severe complications.
How similar studies have performed: While this approach is innovative, similar therapies using stem cells have shown promise in other conditions, suggesting potential for success in this novel application.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Roop, Dennis — University of Colorado Denver
- Study coordinator: Roop, Dennis
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.